InMed Pharmaceuticals Inc.
INM
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.25M | 4.51M | 4.80M | 4.94M | 4.92M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.25M | 4.51M | 4.80M | 4.94M | 4.92M |
| Cost of Revenue | 2.08M | 2.08M | 2.10M | 2.15M | 2.24M |
| Gross Profit | 1.16M | 1.16M | 1.44M | 1.53M | 1.42M |
| SG&A Expenses | 7.15M | 6.99M | 7.09M | 7.05M | 6.56M |
| Depreciation & Amortization | 210.90K | 210.90K | 210.90K | 212.30K | 214.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.79M | 11.03M | 11.41M | 11.55M | 11.69M |
| Operating Income | -8.54M | -7.79M | -7.87M | -7.86M | -8.03M |
| Income Before Tax | -8.34M | -7.61M | -8.16M | -8.11M | -8.25M |
| Income Tax Expenses | -- | -- | -- | -- | 7.10K |
| Earnings from Continuing Operations | -8.34 | -7.61 | -8.16 | -8.11 | -8.26 |
| Earnings from Discontinued Operations | -174.60K | -53.90K | -53.90K | -53.90K | -53.90K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.51M | -7.66M | -8.21M | -8.16M | -8.31M |
| EBIT | -8.54M | -7.79M | -7.87M | -7.86M | -8.03M |
| EBITDA | -8.33M | -7.58M | -7.66M | -7.65M | -7.82M |
| EPS Basic | -2.88 | -4.08 | -7.21 | -9.48 | -12.32 |
| Normalized Basic EPS | -1.77 | -2.52 | -4.48 | -5.90 | -7.66 |
| EPS Diluted | -2.88 | -4.08 | -7.21 | -9.48 | -12.32 |
| Normalized Diluted EPS | -1.77 | -2.52 | -4.48 | -5.90 | -7.66 |
| Average Basic Shares Outstanding | 13.45M | 10.50M | 7.25M | 3.91M | 2.90M |
| Average Diluted Shares Outstanding | 13.45M | 10.50M | 7.25M | 3.91M | 2.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |